No, really, it's not.
There are very similar problems in most of the social AND natural sciences. In 2012, Amgen reported that they could only replicate 6/53 "landmark" cancer studies. Bayer had a similarly hard time replicating papers suggesting new drug targets in a smattering of fields including cardiology and oncology (14/67 successfully replicated).